Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
ONC-392 Plus Lutetium Lu-177 Vipivotide Tetraxetan in Patients with mCRPC (PRESERVE-006)
Phase 1
Last update: May 22
MANDARIN (S6371)
Phase 3
Comparing the Radiopharmaceutical Drug, [Lu-177]Lu-DOTATATE, to Standard of Care Treatment for Patients with Meningioma That Has Come Back After Prior Treatment (MOMENTUM-1)
Phase 2
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients with Newly Diagnosed Large B-Cell Lymphoma
A Dose Finding Study of [Lu-177]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Open-label Study Comparing AAA817 versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [Lu-177]Lu-PSMA Targeted Therapy (PSMAcTION)
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase II Lu-177-DOTATATE Study in Metastatic NPC with a Safety Run-in (SG-AAA-II-01)
Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
N/A